Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged violations of federal securities laws during the Class Period from July 27, 2023, to May 15, 2025 [1] Group 1: Allegations Against UroGen - The lawsuit claims that UroGen and its officers made false or misleading statements regarding the ENVISION clinical study, which was not designed to provide substantial evidence of effectiveness for UGN-102 due to the absence of a concurrent control arm [2] - It is alleged that UroGen failed to heed FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [2] - The misleading statements made by UroGen regarding its business and prospects resulted in significant investor losses when the truth was revealed [2][3] Group 2: Investor Impact - Investors who suffered losses exceeding $50,000 in UroGen's securities are encouraged to participate in the lawsuit, with a deadline to act before July 28, 2025 [3] - The decline in UroGen's stock price following the revelation of the truth has caused significant financial injury to investors [3] Group 3: About the Law Firm - Lowey Dannenberg P.C. is a law firm specializing in representing institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities laws [4] - The firm has a strong track record in prosecuting multi-million-dollar lawsuits and has recovered billions for its clients [4]